Genzyme wins U.S. approval for bone marrow transplant drug

12/15/2008 | Bloomberg · Reuters

The FDA approved Genzyme's Mozobil, a drug capable of boosting the number of bone marrow stem cells that can be used for transplant. The treatment is intended for people with non-Hodgkin's lymphoma or multiple myeloma. The clearance covers Mozobil's use with Amgen's Neupogen and other agents designed to trigger the growth and circulation of bone marrow cells in blood.

View Full Article in:

Bloomberg · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY